STAAR Surgical Announces Preliminary Net Sales Increase for Third Quarter of 2025
Published on October 21, 2025
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced preliminary net sales results for the third quarter ended September 26, 2025. The company reported preliminary net sales of $94.7 million, up 6.9 percent compared with $88.6 million in the same period last year. The company said it is announcing these preliminary results in advance of its quarterly earnings announcement to provide all stockholders with additional information regarding third quarter net sales performance and trends in advance of the STAAR special meeting of stockholders scheduled for October 23, 2025, to vote on the Alcon merger proposal.